Theravance Biopharma/$TBPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Theravance Biopharma
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Ticker
$TBPH
Sector
Primary listing
Employees
90
Headquarters
Website
TBPH Metrics
BasicAdvanced
$858m
8.09
$2.06
0.11
-
Price and volume
Market cap
$858m
Beta
0.11
52-week high
$21.03
52-week low
$8.33
Average daily volume
508k
Financial strength
Current ratio
10.925
Quick ratio
10.728
Long term debt to equity
10.703
Total debt to equity
10.703
Interest coverage (TTM)
-1.46%
Profitability
EBITDA (TTM)
-1.976
Gross margin (TTM)
65.18%
Net profit margin (TTM)
98.54%
Operating margin (TTM)
-3.35%
Effective tax rate (TTM)
18.07%
Revenue per employee (TTM)
$1,190,000
Management effectiveness
Return on assets (TTM)
-0.54%
Return on equity (TTM)
44.85%
Valuation
Price to earnings (TTM)
8.092
Price to revenue (TTM)
7.805
Price to book
2.87
Price to tangible book (TTM)
2.87
Price to free cash flow (TTM)
3.517
Free cash flow yield (TTM)
28.43%
Free cash flow per share (TTM)
4.74
Growth
Revenue change (TTM)
66.92%
Earnings per share change (TTM)
-278.36%
3-year revenue growth (CAGR)
27.91%
10-year revenue growth (CAGR)
9.82%
3-year earnings per share growth (CAGR)
-44.19%
10-year earnings per share growth (CAGR)
-9.08%
What the Analysts think about TBPH
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
TBPH Financial Performance
Revenues and expenses
TBPH Earnings Performance
Company profitability
TBPH News
AllArticlesVideos
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
Business Wire·4 weeks ago
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations
Newsfile Corp·2 months ago
Theravance Biopharma Plummets As Phase 3 Study Falls Short
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Theravance Biopharma stock?
Theravance Biopharma (TBPH) has a market cap of $858M as of April 30, 2026.
What is the P/E ratio for Theravance Biopharma stock?
The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 8.09 as of April 30, 2026.
Does Theravance Biopharma stock pay dividends?
No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of April 30, 2026.
When is the next Theravance Biopharma dividend payment date?
Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Theravance Biopharma?
Theravance Biopharma (TBPH) has a beta rating of 0.11. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.